This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preservedejectionfraction during the session;"Innovations and Insights in Heart Failure With PreservedEjectionFraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preservedejectionfraction during the session;"Innovations and Insights in Heart Failure With PreservedEjectionFraction: Emerging Therapies, Biomarkers and Mechanistic Studies."
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preservedejectionfraction (HFpEF). Pulmonary vascular resistance at rest and exercise decreased with higher BMI.
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] What levels of exercise intensity or duration are beneficial? You research physical activity and cardiovascular health.
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content